Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells $1,103,454.05 in Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Kevin Joseph Fitzgerald sold 2,441 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total transaction of $1,103,454.05. Following the completion of the transaction, the executive vice president owned 25,231 shares of the company’s stock, valued at $11,405,673.55. This trade represents a 8.82% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Kevin Joseph Fitzgerald also recently made the following trade(s):

• On Monday, August 18th, Kevin Joseph Fitzgerald sold 1,396 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $453.27, for a total transaction of $632,764.92.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY opened at $456.35 on Monday. Alnylam Pharmaceuticals, Inc. has a 52 week low of $205.87 and a 52 week high of $484.21. The company has a fifty day simple moving average of $441.57 and a two-hundred day simple moving average of $339.95. The company has a quick ratio of 2.75, a current ratio of 2.80 and a debt-to-equity ratio of 4.10. The company has a market cap of $59.82 billion, a price-to-earnings ratio of -184.76 and a beta of 0.36.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The business had revenue of $773.69 million for the quarter, compared to analysts’ expectations of $633.54 million. During the same period last year, the firm earned ($0.13) earnings per share. The company’s revenue for the quarter was up 17.3% compared to the same quarter last year. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Several hedge funds have recently modified their holdings of the stock. Aaron Wealth Advisors LLC acquired a new position in Alnylam Pharmaceuticals in the 3rd quarter valued at $506,000. GAMMA Investing LLC increased its stake in shares of Alnylam Pharmaceuticals by 13.4% during the third quarter. GAMMA Investing LLC now owns 823 shares of the biopharmaceutical company’s stock worth $375,000 after acquiring an additional 97 shares during the period. Osaic Holdings Inc. raised its holdings in Alnylam Pharmaceuticals by 132.5% during the second quarter. Osaic Holdings Inc. now owns 3,787 shares of the biopharmaceutical company’s stock worth $1,202,000 after purchasing an additional 2,158 shares in the last quarter. Orion Porfolio Solutions LLC raised its holdings in Alnylam Pharmaceuticals by 11.7% during the second quarter. Orion Porfolio Solutions LLC now owns 4,309 shares of the biopharmaceutical company’s stock worth $1,405,000 after purchasing an additional 452 shares in the last quarter. Finally, Hudson Bay Capital Management LP lifted its position in Alnylam Pharmaceuticals by 138.4% in the second quarter. Hudson Bay Capital Management LP now owns 15,348 shares of the biopharmaceutical company’s stock valued at $5,005,000 after purchasing an additional 55,348 shares during the period. 92.97% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ALNY has been the topic of a number of recent research reports. Chardan Capital upped their target price on shares of Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the stock a “buy” rating in a research note on Friday, August 1st. Barclays increased their price objective on shares of Alnylam Pharmaceuticals from $329.00 to $460.00 and gave the company an “overweight” rating in a research report on Friday, August 1st. JPMorgan Chase & Co. lifted their price objective on shares of Alnylam Pharmaceuticals from $348.00 to $475.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 6th. Oppenheimer raised Alnylam Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $490.00 target price on the stock in a report on Monday, August 4th. Finally, BMO Capital Markets lifted their price target on Alnylam Pharmaceuticals from $450.00 to $470.00 and gave the stock an “outperform” rating in a report on Friday, September 5th. Twenty-four analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $439.58.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.